ORION Corp. Stock

Equities

A271560

KR7271560005

Food Processing

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
92,100 KRW -0.32% Intraday chart for ORION Corp. +0.99% -20.67%
Sales 2024 * 3,171B 2.3B Sales 2025 * 3,379B 2.45B Capitalization 3,641B 2.64B
Net income 2024 * 405B 294M Net income 2025 * 437B 317M EV / Sales 2024 * 0.8 x
Net cash position 2024 * 1,118B 812M Net cash position 2025 * 1,578B 1.15B EV / Sales 2025 * 0.61 x
P/E ratio 2024 *
8.94 x
P/E ratio 2025 *
8.31 x
Employees 1,430
Yield 2024 *
1.51%
Yield 2025 *
1.54%
Free-Float 56.15%
More Fundamentals * Assessed data
Dynamic Chart
ORION Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Orion Set to Acquire 25% Stake in LegoChem Biosciences MT
Orion Temporarily Resumes Production of Discontinued Snacks to Offer Young Patients MT
ORION Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer MT
ORION Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Marinus Pharmaceuticals Says European Commission Approves Ztalmy Oral Suspension MT
Orion Corporation Announces European Commission Approval of Ztalmy(R) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder CI
ORION Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Orion Corporation and Amneal Pharmaceuticals, Inc. Sign License Agreement with Amneal Pharmaceuticals, Inc. to Commercialise Amneal's Generic Products in Europe, Australia and New Zealand CI
South Korean Snack Maker Orion Temporarily Closes Tmall Flagship Store MT
Orion Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU CI
Infosys Selected by Finland-Based Orion to Help Transform Its ERP, Planning Platforms MT
Orion's Net Attributable Income Declines 4.3% in September Quarter MT
Marinus Pharmaceuticals Submits NDA to FDA for Seizure Treatment DJ
More news
1 day-0.32%
1 week+0.99%
Current month+1.21%
1 month+1.77%
3 months-0.65%
6 months-23.06%
Current year-20.67%
More quotes
1 week
90 600.00
Extreme 90600
93 800.00
1 month
89 200.00
Extreme 89200
98 600.00
Current year
89 200.00
Extreme 89200
118 700.00
1 year
89 200.00
Extreme 89200
148 100.00
3 years
80 200.00
Extreme 80200
148 100.00
5 years
75 900.00
Extreme 75900
164 500.00
10 years
75 700.00
Extreme 75700
164 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 83-03-31
Members of the board TitleAgeSince
Chairman 68 -
Director/Board Member 64 -
Director/Board Member 72 18-02-28
More insiders
Date Price Change Volume
24-04-25 92,100 -0.32% 145 779
24-04-25 92,400 -0.75% 192,665
24-04-24 93,100 +1.09% 176,242
24-04-23 92,100 -0.43% 145,670
24-04-22 92,500 +2.44% 210,246

End-of-day quote Korea S.E., April 25, 2024

More quotes
Orion Corp is a Korea-based company principally engaged in the manufacturing and distribution of foods. The Company produces and sells confectioneries including biscuits, pies, snacks, candies, gums, chocolates and others. The major products include choco pies, choco chip cookies, Diget, Goraebap and others. The Company distributes its products in domestic and overseas markets such as China, Russia and Vietnam.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
92,100 KRW
Average target price
128,857 KRW
Spread / Average Target
+39.91%
Consensus
  1. Stock Market
  2. Equities
  3. A271560 Stock